ArticleCell stem cell2024
A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS.
Open access · greenAbstract read
In one paragraph
Article in Cell stem cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
14.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 64 citations in OpenAlex.
- "Alkaline-Hammer Strategy" Breaks Acidic and Stromal Barriers to Induce Alkaliptosis and Enhance Immunotherapy in Pancreatic Cancer.Angewandte Chemie (International ed. in English) · 2026Article
- Review
- Recent advancements and limitations of intestinal organoids for clinical applications.Progress in biomedical engineering (Bristol, England) · 2026Review
- Organoids: From Bench to Bedside Applications.MedComm · 2026Review
- Integrated spatial multi-omics delineates fatty acid degradation fuels malignant evolution at the tumour periphery in cervical squamous cell carcinoma.EBioMedicine · 2026Article
- Organoids: technology refining, current applications and future directions.Molecular biomedicine · 2026Review
- The advancements in organoids: Potential and challenges in researching the esophagus and esophageal squamous cell carcinoma.Genes & diseases · 2026Review
- Pan-cancer analysis of cholesterol metabolism reveals the uptake as a modulator of tumor immune features and of the KRAS pathway.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Patient-derived tumor organoids for new drug development: promises and challenges.Investigational new drugs · 2026Review
- KRAS Inhibition in Pancreatic Ductal Adenocarcinoma.Journal of clinical medicine · 2026Review
- Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations.Signal transduction and targeted therapy · 2026Article
- Role of a transmembrane protein, epithelial membrane protein 1, in the pathogenesis of pancreatic ductal adenocarcinoma.Oncogene · 2026Article
- From benchside avatars to bedside breakthroughs: Patient-derived organoids in the new era of cancer immunotherapy.Translational oncology · 2026Review
- Innovative Therapies for Oncogenic KRAS Mutations: Precision Strategies with PROTACs in Cancer Treatment.Anti-cancer agents in medicinal chemistry · 2026Review
- Tumor organoids for testing metabolic flexibility in precision oncology.Frontiers in oncology · 2026Review
- Vortioxetine enhances the anti-pancreatic cancer efficacy of gemcitabine through reducing MAOB expression.Frontiers in pharmacology · 2026Article
- Organoids in Cancer Research and Regenerative Medicine: Current Status, Challenges, and Future Prospects.MedComm · 2026Review
- Organoid research: new concepts and new technologies.Burns & trauma · 2026Review
- OSBPL10 Drives Lipophagy-Mediated Lipid Mobilization to Promote Pancreatic Ductal Adenocarcinoma Progression.International journal of biological sciences · 2026Article
- Review
Corrections and comments
- Commented on by
Authors and funding
14 authors at 2 institutions in 3 countries.
Xiaohua DuanDepartment of Surgery, Weill Cornell Medicine, 1300 York Ave., New York, NY 10065, USA; Center for Genomic Health, 1300 York Ave., New York, NY 10065, USA.
Tuo ZhangGenomics Resources Core Facility, Weill Cornell Medicine, New York, NY 10065, USA.
Lingling FengDepartment of Surgery, Weill Cornell Medicine, 1300 York Ave., New York, NY 10065, USA; Key Laboratory of Pesticide and Chemical Biology (CCNU), Ministry of Education, College of Chemistry, Central China Normal University, Wuhan, Hubei 430079, China.
Neranjan de SilvaDepartment of Surgery, Weill Cornell Medicine, 1300 York Ave., New York, NY 10065, USA.
Benjamin GreenspunDepartment of Surgery, Weill Cornell Medicine, 1300 York Ave., New York, NY 10065, USA; Center for Genomic Health, 1300 York Ave., New York, NY 10065, USA.
Xing WangGenomics Resources Core Facility, Weill Cornell Medicine, New York, NY 10065, USA.
Jenna MoyerCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
M Laura MartinCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
Rohit ChandwaniDepartment of Surgery, Weill Cornell Medicine, 1300 York Ave., New York, NY 10065, USA; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA.
Olivier ElementoCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
Steven D LeachDartmouth Cancer Center, Dartmouth College, Hanover, NH 03755, USA.
Todd EvansDepartment of Surgery, Weill Cornell Medicine, 1300 York Ave., New York, NY 10065, USA; Center for Genomic Health, 1300 York Ave., New York, NY 10065, USA. Electronic address: tre2003@med.cornell.edu.
Shuibing ChenDepartment of Surgery, Weill Cornell Medicine, 1300 York Ave., New York, NY 10065, USA; Center for Genomic Health, 1300 York Ave., New York, NY 10065, USA. Electronic address: shc2034@med.cornell.edu.
Fong Cheng PanDepartment of Surgery, Weill Cornell Medicine, 1300 York Ave., New York, NY 10065, USA. Electronic address: fpan12@gmail.com.
Cornell University · USDartmouth College · US
Funding
Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Steven D Leach · 1985 to 2026
$91.3MThe Prrx-1 transcription factor in pancreatic ductal biologyR01DK060694 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI CHANDWANI, ROHIT, RUSTGI, ANIL K · 2002 to 2025
$8.3MDetermining the Intrinsic and Environmental Signal Contributing to Early T1D ProgressionU01DK127777 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI CHEN, SHUIBING, PARKER, STEPHEN CJ · 2020 to 2023
$3.0MMetallothionein 1E as a Central Regulator of Human Pancreatic Beta Cell Function and SurvivalR01DK119667 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI CHEN, SHUIBING · 2019 to 2022
$2.5MComprehensive genetic dissection of druggable KRAS targetsR01CA204228 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LEACH, STEVEN D · 2016 to 2020
$1.9MDecode the Impact of SARS-CoV-2 on Human PancreasR01DK130454 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI CHEN, SHUIBING, LIM, JEAN KYOU · 2021 to 2023
$1.3MNCI NIH HHS P30 CA023108NCI NIH HHS R01 CA204228NIDDK NIH HHS R01 DK060694NIDDK NIH HHS R01 DK119667NIDDK NIH HHS R01 DK130454NIDDK NIH HHS U01 DK127777
Abstract
KRAS mutations, mainly G12D and G12V, are found in more than 90% of pancreatic ductal adenocarcinoma (PDAC) cases. The success of drugs targeting KRAS
Indexed as
Carcinoma, Pancreatic DuctalPancreatic NeoplasmsAnimalsCholesterolHumansMiceMutationOrganoidsProto-Oncogene Proteins p21(ras)CholesterolKRAS protein, humanProto-Oncogene Proteins p21(ras)cholesterol biosynthesiscolon cancer organoidsKRASlung cancer organoidsorthotopic transplantationpancreatic organoidperhexiline maleateSREBP2targeted therapy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.